Optic Neuritis Treatment Trial (ONTT)



Objective

To evaluate the benefit of corticosteroids as a treatment for optic neuritis. Do oral or IV corticosteroids improve visual outcomes and/or speed recovery? Are there complications?

Methods

Design: RCT

Sample Size: 457

N = 319 at 10 year follow up

• N = 389 at 15 year follow up

Treatment Groups:

- 150 to placebo
- 151 to IV methylprednisolone
- 156 to oral prednisone

Outcome Measures:

- Primary: Visual Field & Contrast Sensitivity
- Secondary: Visual Acuity (VA) & Color Vision
- Long term: development of MS

Results

Point 1: IV methylprednisolone group had quicker recovery of vision versus placebo

- P = 0.0001 for visual field, P = 0.02 for contrast sensitivity, P = 0.09 for VA
- Oral prednisone group did not have statistically significant quicker recovery

Point 2: No difference in visual acuity at 6 months between groups

 Though IV methylpred group had slightly better visual field, contrast sensitivity, and color vision

Point 3: Oral prednisone group had higher incidence repeat optic neuritis

• Relative risk of optic neuritis was 1.79 for oral pred group compared to placebo (0.81 for IV methylpred group)

Point 4: Development of MS diagnosis at 15 years was 50% overall

• Only 25% if no baseline MRI lesions, increased to 72% if 1 or more lesions

Point 5: Long-term VA (10-year) was good (69% had 20/20 in both eyes)

Patients with MS were more likely to have repeat events and worse vision

TLDR: Treatment of acute optic neuritis with IV methylprednisolone accelerated visual recovery, whereas oral prednisone led to increased episodes of repeat optic neuritis.

Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. *N Engl J Med*. 1992 Feb 27;326(9):581-8. doi: 10.1056/NEJM199202273260901. PMID: 1734247.

Beck RW, Gal RL, Bhatti MT, et al.; Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. *Am J Ophthalmol*. 2004 Jan;137(1):77-83. doi: 10.1016/s0002-9394(03)00862-6. PMID: 14700647.

Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008 Jun;65(6):727-32. doi: 10.1001/archneur.65.6.727. PMID: 18541792; PMCID: PMC2440583.